Study on Phenotypic Characterization of Combined Pulmonary Fibrosis and Emphysema
This study is to evaluate the expression of biological markers in induced sputum and peripheral blood T lymphocytes of patients with combined pulmonary fibrosis and emphysema (CPFE). The features of CPFE would be observed, including pulmonary function tests and fractional exhaled nitric oxide （FENO）.
|Study Design:||Observational Model: Case Control
Time Perspective: Cross-Sectional
|Official Title:||Study on Phenotypic Characterization of Combined Pulmonary Fibrosis and Emphysema|
- the expression of CXCR3 in blood by flow cytometry and the chemokine IL-4,IFN-γ,CXCL9,CXCL10,CXCL11 and CCL17 in sputum and blood [ Time Frame: six months ] [ Designated as safety issue: Yes ]
- pulmonary function tests [ Time Frame: six months ] [ Designated as safety issue: Yes ]
- fractional exhaled nitric oxide （FENO） [ Time Frame: six months ] [ Designated as safety issue: Yes ]
Biospecimen Retention: Samples Without DNA
whole blood, serum, sputum
|Study Start Date:||May 2010|
|Study Completion Date:||June 2011|
|Primary Completion Date:||June 2011 (Final data collection date for primary outcome measure)|
A new disease including concomitant upper-lobe emphysema and lower-lobe fibrosis in radiology has been defined as (combined pulmonary fibrosis and emphysema, CPFE). CPFE has distinct clinical characteristics with the emphysema and the pulmonary fibrosis, including gender, age, clinical manifestation, pulmonary function tests and prognosis.
Normally Th1/Th2 is balanced. However, patients with emphysema had a significantly higher expression of Th1. On the other hand, higher expression of Th2 is involved in the development of pulmonary fibrosis. The expressions of Th1 and Th2 were proved to play a central role in pathogenesis of emphysema and pulmonary fibrosis, while are still unknown in patients of combined pulmonary fibrosis and emphysema. The study would observe the Th1/Th2 expression, pulmonary function tests , fractional exhaled nitric oxide （FENO）and other features in CPFE patients.
Please refer to this study by its ClinicalTrials.gov identifier: NCT01121367
|Beijing chaoyang hospital-affiliate of captial medical university|
|Beijing, Beijing, China, 100020|
|Principal Investigator:||kewu huang, MD||Beijing Chao Yang Hospital|